A 6‐month, open‐label study of memantine in patients with frontotemporal dementia

Diehl‐Schmid, Janine; Förstl, Hans; Perneczky, Robert; Pohl, C.; Kurz, Alexander

doi:10.1002/gps.1973

Cited by 87 publications

(53 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Memantine is usually prescribed for bvFTD patients by half of the physicians surveyed in this study. Some recent preliminary studies have argued for the benefits of this uncompetitive antagonist of the N-methyl-D-aspartate glutamate receptor on the behavioral disturbances of bvFTD patients (Boxer et al 2009;Diehl-Schmid et al 2008;Kavirajan 2009;Swanberg 2007;Vossel and Miller 2008). Nonpharmacological treatment was usually indicated by almost half of the participants in this study, who also very frequently suggested psychotherapy for relatives of bvFTD patients.…”

Section: Diagnosis and Treatment Of Bvftdmentioning

confidence: 88%

How Much Do Physicians in Latin America Know About Behavioral Variant Frontotemporal Dementia?

Gleichgerrcht

Flichtentrei²,

Manes

2011

J Mol Neurosci

View full text Add to dashboard Cite

Diagnosis of behavioral variant frontotemporal dementia (bvFTD) can be especially challenging during the early stages for several reasons, including the fact that (a) behavioral disturbances in bvFTD can mimic the symptomatic profile of psychiatric disorders; (b) neuropsychological performance may be relatively spared; and (c) changes in structural neuroimaging may go undetected. Most frequently, bvFTD is not included as part of medical or residency training outside the field of cognitive neurology. The present study aimed at examining bvFTD-related practices concerning academic and professional training, diagnosis, and treatment across Latin America. We surveyed the academic and professional aspects of clinical practice related to bvFTD of 596 physicians from different fields throughout the continent. We discuss several aspects concerning Latin American physicians' training on dementia and bvFTD, the way in which they approach the differential diagnosis of bvFTD, and their most frequent strategies for the treatment of this condition. We conclude that information about bvFTD deserves more attention in both undergraduate and postgraduate medical education in Latin America, and that understanding clinical practices related to FTD can help design more efficient training programs for physicians in this and other world regions.

show abstract

Section: Diagnosis and Treatment Of Bvftdmentioning

confidence: 88%

How Much Do Physicians in Latin America Know About Behavioral Variant Frontotemporal Dementia?

Gleichgerrcht

Flichtentrei²,

Manes

2011

J Mol Neurosci

View full text Add to dashboard Cite

show abstract

“…119 For the management of cognitive symptoms related to FTD, several open label studies have demonstrated benefit in patients who were treated with NMDA antagonist (memantine) with doses up to 20mg/day. 120 In an open label study of 16 121 However a recent RCT of 81 patients did not demonstrate a clear benefit with NMDA antagonist (memantine). 122 The choice of acetylcholinesterase inhibitors should be based upon factors such as experience of the clinician, tolerance to side effects, ease of use, and the clinical profile of the individual to be treated.…”

Section: Frontotemporal Dementiamentioning

confidence: 98%

Systematic review of recent dementia practice guidelines

2014

View full text Add to dashboard Cite

Level Type of Evidence + +High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias. +Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias. -Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias + +High quality systematic reviews of case control or cohort studies. High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal 2 + Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal -Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal 3Non-analytic studies, e.g. case reports, case series 4 Expert opinion Levels of evidence and grades of recommendation Statement of IntentThese guidelines are not intended to serve as a standard of medical care. Standards of medical care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge advances and patterns of care evolve.The contents of this publication are guidelines to clinical practice, based on the best available evidence at the time of development. Adherence to these guidelines may not ensure a successful outcome in every case. These guidelines should neither be construed as including all proper methods of care, nor exclude other acceptable methods of care. Each physician is ultimately responsible for the management of his/her unique patient, in the light of the clinical data presented by the patient and the diagnostic and treatment options available. ForewordDementia represents a major public health concern in Singapore and worldwide. Being the most prevalent neurodegenerative disease, dementia is expected to affect 55,000 patients in Singapore by the year 2020. The commonest cause of dementia is Alzheimer's disease with vascular dementia being the next most important cause. Right from the stage of mild dementia up to the stages of severe dementia, this condition poses a significant health and socio-economic burden to patients, caregivers and the nation as a whole. Early diagnosis will allow appropriate use of pharmacological and non-pharmacological management. Along with disease stabilization, efforts to address caregiver burden, patient safety and medico legal concerns should form the principles of management. Clear practise guidelines will allow holistic and optimal care in dementia.I am pleased to present the revised clinical practise guidelines for dementia. In this regard the workgroup has performed a thorough review of the existing literature to recommend both pharmacological and nonpharmacological aspects of management for patients ranging from mild cognitive impairment to severe dementia. This revised guidelines also highlights issues related to the management of mild cognitive impairment, young onset dementia and e...

show abstract

“…[26][27][28]30,32,34 However, the Bromocriptine study showed a significant improvement in the mean time of utterance as compared to the placebo, 31 and one Memantine study found a significant increase in the total score of ADAS-Cog. 35 36 Two B studies did not evaluate cognitive functions. 12,33 The quality C studies showed a significant improvement in behavior with Selegiline.…”

Section: Resultsmentioning

confidence: 99%

Pharmacological treatment of frontotemporal lobar degeneration: systematic review

Portugal

Marinho

Laks

2011

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: To identify the therapeutic options available for treatment of cognitive and behavioral symptoms in frontotemporal lobar degeneration. Method: Systematic review using the descriptors "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR "fronto-temporal dementia" OR "fronto-temporal degeneration" OR "Pick's disease" OR "Pick's atrophy" OR "semantic dementia" OR "progressive aphasia" AND "pharmacotherapy" OR "treatment" OR "efficacy" OR "effects" OR "management" was performed in the Medline and Lilacs databases. Selection criteria: Quality A -randomized clinical trials. Quality Bopen studies or reports of six or more cases. Quality C -reports of five or fewer cases. Two reviewers independently assessed the clinical studies. Information collected included diagnostic criteria used, sample size, duration, efficacy and tolerability measures used and results obtained. Results: From the 532 studies found, 29 complied with the inclusion criteria. All studies worked with a small sample, had short duration of treatment and used non-uniform measures in evaluating efficacy and tolerability. Studies showed disparate results with respect to behavior and cognition. Conclusion: There is still little, and poor, evidence available for treatment of frontotemporal lobar degeneration and studies with better methodological background are needed. Descriptors IntroductionThe clinical syndromes related to frontotemporal lobar degeneration (FTLD) are the second most common cause of pre-senile primary dementia. 1 A recent Brazilian epidemiological study found a dementia prevalence of 7.1% in individuals over

show abstract

A 6‐month, open‐label study of memantine in patients with frontotemporal dementia

Abstract: The number of patients was small, so that the evidence given by statistical tests is limited. Thus, the present study can only show trends regarding drug effects. As memantine is well-tolerated, further randomized and controlled studies should be conducted to evaluate drug efficacy.

Cited by 87 publications

References 33 publications

How Much Do Physicians in Latin America Know About Behavioral Variant Frontotemporal Dementia?

How Much Do Physicians in Latin America Know About Behavioral Variant Frontotemporal Dementia?

Systematic review of recent dementia practice guidelines

Pharmacological treatment of frontotemporal lobar degeneration: systematic review

Contact Info

Product

Resources

About